Hansoh Pharma Submits NDA for Novel GLP-1/GIP Dual Agonist Olezypeptide Injection for Chronic Weight Management

On June 4, Hansoh Pharma announced that the company’s innovative drugOnce-Weekly Subcutaneous GLP-1/GIP Receptor Dual AgonistOlepatide InjectionNew Drug Application (NDA) accepted by the National Medical Products Administration (NMPA) of China,Indicated for long-term weight management in adults with obesity or overweight.

Olapertide（HS-20094）It is independently developed by Hansoh Pharma.Glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist, by selectively activating GLP-1/GIP receptors, it modulates metabolic pathways associated with appetite control, glucose metabolism, and energy balance, thereby producing biological effects such as glycemic control and weight reduction. It is administered via subcutaneous injection once weekly.

According to a press release from Hansoh Pharma, in March 2026, the first Phase 3 clinical trial (HS-20094-301) of olepatide in adult subjects with overweight or obesity in China met its primary endpoint.After 48 weeks of treatment with orforglipron, the mean weight reduction from baseline reached up to 19.3%, and the proportion of subjects achieving a weight reduction of ≥5% was as high as 97.2%.Studies have shown that the orforglipron treatment group demonstrated excellent gastrointestinal tolerability, with an average incidence of nausea <10% and vomiting <5%. Compared to published phase 3 trial data for existing GLP-1-related dual agonists, it exhibited lower rates of gastrointestinal adverse events and treatment discontinuation.

On June 2, 2025, Hansoh Pharma announced that it had entered into a licensing agreement with Regeneron Pharmaceuticals, granting Regeneron the exclusive global license (excluding mainland China, Hong Kong, and Macau) to develop, manufacture, and commercialize HS-20094.

References:

[1]Hansoh Pharma | NMPA Accepts Marketing Authorization Application for Orlabrutide Injection, an Innovative Dual GLP-1/GIP Target Weight-Loss Drug